Acceptability of aspirin for cancer preventive therapy: a survey and qualitative study exploring the views of the UK general population.
Kelly E LloydLouise H HallLucy ZieglerRobbie FoySophie M C GreenMairead MacKenzieDavid G TaylorSamuel George Smithnull nullPublished in: BMJ open (2023)
Among the general population, those with a personal or family history of cancer may be more receptive towards taking aspirin for preventive therapy. Future policies and campaigns recommending aspirin may be of particular interest to these groups. Multiple considerations about the benefits and risks of aspirin highlight the need to support informed decisions on the medication.
Keyphrases
- low dose
- cardiovascular events
- papillary thyroid
- antiplatelet therapy
- squamous cell
- public health
- anti inflammatory drugs
- healthcare
- cardiovascular disease
- lymph node metastasis
- stem cells
- childhood cancer
- emergency department
- current status
- cross sectional
- percutaneous coronary intervention
- bone marrow
- climate change